MAB10753
Anti-Caspase3 (active form) Antibody, clone 3D9.3
clone 3D9.3, from mouse
Synonym(s):
Caspase-3, CASP-3, Apopain, Cysteine protease CPP32, CPP-32, Protein Yama, SREBP cleavage activity 1, SCA-1, Caspase-3 subunit p17, Caspase-3 subunit p12
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
3D9.3, monoclonal
species reactivity
human
technique(s)
flow cytometry: suitable
immunocytochemistry: suitable
western blot: suitable
isotype
IgMκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CASP3(836)
General description
Caspase-3 (CPP32, Apopain) is the most extensively studied apoptotic protein. Caspase-3 is synthesized as an inactive proenzyme (32 kDa) that is processed in cells undergoing apoptosis by self-proteolysis and/or cleavage by another upstream protease. The processed form of caspase-3 consists of large (17 kDa) and small (12 kDa) subunits which associate to form an active enzyme. The active caspase-3 proteolytically cleaves and activates other caspases, as well as relevant targets in the cells such as PARP and DFF.
Specificity
This antibody demonstrates specificity for the cleaved 17 kDa active form, but does not cross-react with the non-active (pro) form Caspase3 at 35 kDa.
Immunogen
KLH-conjugated linear peptide corresponding to human Caspase3 (active form).
Application
Anti-Caspase3 (active form), clone 3D9.3 is an antibody targeting the Caspase3 (active form) protein, validated for use in WB, ICC & Flow.
Immunocytochemistry Analysis: A 1:500 dilution from a representative lot detected Caspase3 (active form) in Hela and Hela/staurosporine 3 hr cells.
Flow Cytometry Analysis: A 1:400 dilution from a representative lot detected Caspase3 (active form) in Jurkat T cells.
Flow Cytometry Analysis: A 1:400 dilution from a representative lot detected Caspase3 (active form) in Jurkat T cells.
Quality
Evaluated by Western Blot in HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL of this antibody detected Caspase3 (active form) in 10 µg of HeLa and staurosporine treated HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL of this antibody detected Caspase3 (active form) in 10 µg of HeLa and staurosporine treated HeLa cell lysate.
Target description
~17 kDa observed. Caspase3 is cleaved during apoptosis into 17 kDa and 12 kDa active forms.
Linkage
Replaces: 04-1090; 04-439
Physical form
Format: Purified
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Catalina Silva-Hirschberg et al.
Therapeutic advances in medical oncology, 11, 1758835919891567-1758835919891567 (2019-12-17)
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of primary cutaneous lymphomas and represent complex diseases regarding their physiopathology and management. Depending on the stage of the disease, different treatment regimens are applied, but there is no consensus on
Erdal Erkoç et al.
Turkish archives of otorhinolaryngology, 61(3), 124-133 (2023-11-29)
To investigate the effects of cross-linked hyaluronic acid (CLHA) in an experimental model of vestibulotoxicity and cochleotoxicity. Twenty-eight female Wistar albino rats (200-250 g) were divided into four groups. Group A received 0.06 mL of 13.33 mg/mL gentamicin, Group B
Axel H Schönthal et al.
Cancers, 13(14) (2021-07-25)
Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which typically includes cytarabine (AraC), either alone or in combination with
John Chun-Hao Chen et al.
Oncology letters, 17(1), 638-645 (2019-01-19)
Trichostatin A (TSA), a hydroxamate histone deacetylase inhibitor, is a compound that has been identified to induce anticancer activity. The aim of the present study was to investigate whether sorafenib, in combination with TSA, was able to augment the anticancer
Ya-Jing Zhang et al.
Toxicology research, 10(5), 1052-1063 (2021-11-05)
Cancer is one of the leading causes of death in the world. It is very important to find drugs with high efficiency, low toxicity, and low side effects for the treatment of cancer. Flavonoids and their derivatives with broad biological
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service